World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
31236
World Ranking
18635
National Ranking
9282

Craig L. Leonardi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Craig L. Leonardi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 244 publications — 7th percentile

7% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Craig L. Leonardi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Craig L. Leonardi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Craig L. Leonardi is affiliated with Saint Louis University in the United States. Their research primarily focuses on the field of Medicine with a strong emphasis on Immunology and Microbiology. Within these broad domains, their work covers multiple subfields including Immunology, Dermatology, Pathology and Forensic Medicine, Economics and Econometrics, and Oncology.

Leonardi's research extensively addresses topics related to Psoriasis, including its treatment and pathogenesis. Other significant topics in their work include Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Biosimilars and Bioanalytical Methods, Pharmaceutical Studies and Practices, and Drug-Induced Adverse Reactions.

The scientist has published in several reputable venues with multiple contributions. Frequent publication venues include:

  • Journal of the American Academy of Dermatology
  • Dermatology and Therapy
  • Journal of Psoriasis and Psoriatic Arthritis
  • Advances in Therapy
  • JAMA Dermatology

Several recent papers authored or coauthored by Leonardi demonstrate their ongoing engagement in clinical research related to psoriasis and dermatologic therapies. Notable publications include:

  • "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies," 2020, Journal of the American Academy of Dermatology
  • "Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures," 2020, Journal of the American Academy of Dermatology
  • "Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis," 2020, JAMA Dermatology
  • "Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials," 2020, Dermatology and Therapy
  • "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis," 2022, Dermatology and Therapy

Leonardi frequently collaborates with other researchers in the field. Frequent coauthors include Russel Burge, Mark Lebwohl, April W. Armstrong, Andrew Blauvelt, and Kim Papp.

Best Publications

  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Craig L Leonardi;Alexa B Kimball;Kim A Papp;Newman Yeilding

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

    Alan Menter;Alice Gottlieb;Steven R. Feldman;Abby S. Van Voorhees

  • Etanercept as monotherapy in patients with psoriasis

    Craig L. Leonardi;Jerold L. Powers;Robert T. Matheson;Bernard S. Goffe

  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Stephen Tyring;Alice Gottlieb;Kim Papp;Ken Gordon

  • Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

    Kim A Papp;Craig Leonardi;Alan Menter;Jean-Paul Ortonne

  • Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

    Craig Leonardi;Robert Matheson;Claus Zachariae;Gregory Cameron

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

    Alice Gottlieb;Neil J. Korman;Kenneth B. Gordon;Steven R. Feldman

  • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

    Gerald G. Krueger;Richard G. Langley;Craig Leonardi;Newman Yeilding

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • European S3-guidelines on the systemic treatment of psoriasis vulgaris

    D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

    Alan Menter;Bruce E. Strober;Daniel H. Kaplan;Dario Kivelevitch

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

    Kenneth B. Gordon;Richard G. Langley;Craig Leonardi;Darryl Toth

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

    Craig A. Elmets;Craig L. Leonardi;Dawn M.R. Davis;Joel M. Gelfand

  • Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

    Robert E. Kalb;David F. Fiorentino;Mark G. Lebwohl;John Toole

  • A classification of psoriasis vulgaris according to phenotype

    C. E M Griffiths;E. Christophers;J. N W N Barker;R. J G Chalmers

  • Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

    Howard Sofen;Stacy Smith;Robert T. Matheson;Craig L. Leonardi

  • Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

    Peter C.M. van de Kerkhof;Christopher E.M. Griffiths;Kristian Reich;Craig L. Leonardi

Frequent Co-Authors

Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kim Papp
Kim Papp Probity Medical Research
Alan Menter
Alan Menter Texas A&M University
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Kristian Reich
Kristian Reich University of Göttingen
Richard G. Langley
Richard G. Langley Dalhousie University
Craig A. Elmets
Craig A. Elmets University of Alabama at Birmingham
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical degree in the USA often leads to a variety of career options, both clinical and non-clinical. For those interested in healthcare leadership, a health administration degree prepares graduates for roles in hospital management, policy analysis, and healthcare consulting.

If you are looking to advance further, there are many affordable mha online programs designed for future healthcare executives. These courses focus on strategic planning, finance, and organizational leadership in healthcare settings.

For registered nurses, msn to dnp programs online offer a streamlined path to a Doctor of Nursing Practice, enabling advanced practice, leadership, and teaching roles.

Pharmacists can also earn advanced qualifications with flexible pharmd online programs, expanding their expertise and career opportunities in clinical or research settings.

These options can help broaden your impact on the healthcare industry—even beyond direct patient care.

Best Scientists Citing Craig L. Leonardi

Trending Scientists

Recently Published Articles